scholarly journals Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

2018 ◽  
Vol 91 (1091) ◽  
pp. 20180308 ◽  
Author(s):  
Harshad R Kulkarni ◽  
Aviral Singh ◽  
Thomas Langbein ◽  
Christiane Schuchardt ◽  
Dirk Mueller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Molecular Radiotherapy ◽  
Specific Membrane

scholarly journals Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI

Nanoscale ◽  
2016 ◽  
Vol 8 (25) ◽  
pp. 12668-12682 ◽  
Author(s):  
Fan Pu ◽  
Mani Salarian ◽  
Shenghui Xue ◽  
Jingjuan Qiao ◽  
Jie Feng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Imaging ◽  
Contrast Agents ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer

2009 ◽  
Vol 69 (17) ◽  
pp. 6932-6940 ◽  
Author(s):  
Shawn M. Hillier ◽  
Kevin P. Maresca ◽  
Frank J. Femia ◽  
John C. Marquis ◽  
Catherine A. Foss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Preclinical Evaluation ◽  
Specific Membrane

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

scholarly journals 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

2021 ◽  
Vol 10 (5) ◽  
pp. 205846012110225
Author(s):  
Omer Aras ◽  
Stefan Harmsen ◽  
Richard Ting ◽  
Haluk B Sayman
Keyword(s):  
Prostate Cancer ◽  
Standard Of Care ◽  
Complete Response ◽  
Prostate Specific Membrane Antigen ◽  
Limited Data ◽  
Castrate Resistant Prostate Cancer ◽  
Targeting Peptide ◽  
Castrate Resistant ◽  
Specific Membrane

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document